Search
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hy...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesVildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigationalVildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...
Categories: P-glycoprotein substratesLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and i...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2D6 InhibitorsSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalSofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-strand...
Categories: P-glycoprotein substratesIndalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIndalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFluocortolone
go.drugbank.com/drugs/DB08971ApprovedWithdrawnFluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers